What is Cagrilintide?
Cagrilintide is an investigational (still in trials) once weekly amylin analog, a lab-made version of a pancreas hormone that reduces appetite through a different pathway from GLP-1 drugs, and it is being developed mainly as CagriSema, a fixed combination with semaglutide 2.4 mg. Alone it produced 10.8% weight loss at 4.5 mg over 26 weeks in a phase 2 trial of 706 people, and CagriSema produced 20.4% weight loss at 68 weeks in adults without diabetes (REDEFINE 1, 3,417 people) and 13.7% in adults with type 2 diabetes (REDEFINE 2, 1,206 people). As of September 2026 neither form is FDA approved, neither can lawfully be compounded (custom-made by a pharmacy), and cagrilintide is prohibited in sport under WADA section S0, the anti-doping ban on unapproved substances.
Cagrilintide is an investigational long acting amylin analog (acylated, once weekly), developed alone and in fixed combination with semaglutide 2.4 mg. It is also known as AM833, NN9838, CagriSema (with semaglutide), long acting amylin analog, cagrilintide semaglutide, Cagri-Sema.
How does it work?
Cagrilintide is an analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. It activates amylin receptors and calcitonin receptors in the area postrema and hypothalamus, slowing gastric emptying, suppressing glucagon, and increasing satiety. Because this pathway is separate from GLP-1 signaling, combining it with semaglutide produces additive weight loss. A fatty acid side chain binds albumin for once weekly dosing.
| Cluster | GLP-1 and incretin agonists |
|---|---|
| Routes | Subcutaneous injection once weekly (clinical trials only) |
| Conditions studied | Obesity and chronic weight management; Type 2 diabetes |
| Record | v3, reviewed, verified Sep 27, 2026 |
What does the evidence say about Cagrilintide?
One phase 2 monotherapy trial (n = 706, 26 weeks) and a phase 3 program for the semaglutide combination. Alone, cagrilintide 0.3 to 4.5 mg produced 6.0% to 10.8% weight loss versus 3.0% on placebo. In REDEFINE 1 (n = 3,417, 68 weeks) the combination produced 20.4% weight loss versus 3.0% on placebo; in REDEFINE 2 (n = 1,206, 68 weeks, type 2 diabetes) 13.7% versus 3.4%; and in REDEFINE 5 (n = 331, East Asia) it beat semaglutide alone by 6.5 percentage points. In the open label REDEFINE 4 trial (n = 809, 84 weeks) the combination produced 23.0% weight loss versus 25.5% with tirzepatide 15 mg and missed non-inferiority (manufacturer topline, not peer reviewed). In type 2 diabetes, three published phase 3 trials support the combination: REIMAGINE 2 (n = 2,713, 68 weeks, on metformin with or without an SGLT2 inhibitor) found it superior to semaglutide 2.4 mg alone on HbA1c (minus 1.91 versus minus 1.75 points); REIMAGINE 1 (n = 189, 40 weeks, not controlled by diet and exercise alone) showed HbA1c minus 1.8 versus minus 0.1 points and weight minus 13.8% versus minus 1.4% on placebo; and REIMAGINE 3 (n = 274, 40 weeks, added to basal insulin) showed HbA1c minus 2.33 versus minus 0.66 points with 10% to 12% weight loss. An earlier phase 2 trial (n = 92, 32 weeks) showed similar direction of effect.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 8 | 8928 |
| Human observational studies | 0 | n/a |
| Animal studies | 0 | n/a |
| All indexed studies | 8 | 8,928 |
Human evidence
Phase 2 monotherapy (Lau 2021): 706 adults without diabetes with BMI 30 or higher (or 27 with a comorbidity), 26 weeks; weight loss 6.0% to 10.8% across 0.3 to 4.5 mg versus 3.0% on placebo, and 10.8% with 4.5 mg versus 9.0% with liraglutide 3.0 mg. REDEFINE 1 (Garvey 2025): 3,417 adults without diabetes, 68 weeks; estimated mean weight change minus 20.4% with cagrilintide 2.4 mg plus semaglutide 2.4 mg versus minus 3.0% with placebo (difference 17.3 percentage points). REDEFINE 5 (2026): 331 adults in Japan and Taiwan, 68 weeks; minus 18.4% with the combination versus minus 11.9% with semaglutide alone. Phase 2 type 2 diabetes (Frias 2023): 92 adults, 32 weeks, clinically relevant HbA1c improvement with the combination.
Animal evidence
Rodent pharmacology established amylin receptor mediated reductions in food intake and body weight and the additive effect with GLP-1 receptor agonists. No labeling exists because the drug is not approved.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial2021 PMID 34798060 | Randomized, double blind, placebo and active (liraglutide 3.0 mg) controlled dose finding trial, 26 weeksn = 706 Adults without diabetes with BMI 30 or higher, or 27 or higher with a comorbidity | Weight loss 6.0% to 10.8% across 0.3 to 4.5 mg versus 3.0% placebo; 4.5 mg beat liraglutide 3.0 mg (10.8% versus 9.0%) | Evidence: Human RCT evidence |
| Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1)2025 PMID 40544433 | Randomized, double blind, placebo and active controlled phase 3a trial, 68 weeksn = 3,417 Adults without diabetes with BMI 30 or higher, or 27 or higher with a complication | Estimated mean weight change minus 20.4% with cagrilintide 2.4 mg plus semaglutide 2.4 mg versus minus 3.0% placebo | Evidence: Human RCT evidence |
| Co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity in Japan and Taiwan (REDEFINE 5)2026 PMID 42009015 | Randomized, double blind, active controlled phase 3a trial, 68 weeksn = 331 Adults in Japan and Taiwan with BMI 27 or higher, with or without type 2 diabetes | Weight change minus 18.4% with the combination versus minus 11.9% with semaglutide alone (difference minus 6.5 percentage points) | Evidence: Human RCT evidence |
| Co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes: a phase 2 trial2023 PMID 37364590 | Randomized, double blind, active controlled phase 2 trial, 32 weeksn = 92 Adults with type 2 diabetes and BMI 27 or higher | Clinically relevant improvements in HbA1c and continuous glucose monitoring measures with the combination versus each drug alone | Evidence: Human RCT evidence |
| Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2)2025 PMID 40544432 | Phase 3 randomized, double-blind, placebo-controlled trial, 68 weeksn = 1,206 Adults with overweight or obesity and type 2 diabetes | Mean body weight change minus 13.7% with cagrilintide 2.4 mg plus semaglutide 2.4 mg versus minus 3.4% with placebo; HbA1c of 6.5% or less in 73.5% versus 15.9% | Evidence: Human RCT evidence |
| Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2)2026 PMID 42251859 | Randomized, double blind, placebo and active controlled phase 3 trial, 68 weeksn = 2,713 Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor and BMI 25 or higher | HbA1c change minus 1.91 points with cagrilintide and semaglutide 2.4 mg each versus minus 1.75 with semaglutide 2.4 mg alone (superior) | Evidence: Human RCT evidence |
| Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1)2026 PMID 42251860 | Randomized, double blind, placebo controlled phase 3a trial, 40 weeksn = 189 Adults with type 2 diabetes not controlled by diet and exercise alone | HbA1c minus 1.8 versus minus 0.1 points and body weight minus 13.8% versus minus 1.4% on placebo (efficacy estimand) | Evidence: Human RCT evidence |
| Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3)2026 PMID 42251856 | Randomized, double blind, placebo controlled phase 3a trial, 40 weeksn = 274 Adults with type 2 diabetes on stable basal insulin with or without metformin | HbA1c minus 2.33 points (2.4 mg each) versus minus 0.66 on placebo (efficacy estimand), with 10% to 12% weight loss on the combination | Evidence: Human RCT evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Obesity and chronic weight management | Evidence: Human RCT evidence | Amylin analog studied alone and with semaglutide; not FDA approved. |
| Type 2 diabetes | Not graded | Several peptide drugs are FDA approved for type 2 diabetes, including insulin, GLP-1 receptor agonists, tirzepatide, and pramlintide. GLP-1 agonists and tirzepatide lower HbA1c by about 1 to 2 percentage points and reduce weight; semaglutide also reduces cardiovascular events. |
Is Cagrilintide legal in the United States?
FDA and compounding status
Not FDA approved as of the last verification date, either alone or in the fixed combination with semaglutide. Because cagrilintide is not a component of an approved drug, has no USP monograph, and is not on the 503A bulks list, it has no federal basis to be compounded. Any product sold as cagrilintide or CagriSema outside a clinical trial is an unapproved drug. Check FDA for the status of any marketing application before relying on this record.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
No regulatory events recorded.
Full tracker for Cagrilintide or the category-wide tracker.
Email me when Cagrilintide's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of Cagrilintide used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Monotherapy phase 2: once weekly subcutaneous cagrilintide escalated to maintenance doses of 0.3, 0.6, 1.2, 2.4, or 4.5 mg. Phase 3 combination: cagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly after a 16 week escalation. No approved label exists; these are trial regimens only.
Routes reported
| # | Route |
|---|---|
| 1 | Subcutaneous injection once weekly (clinical trials only) |
What are the side effects and interactions of Cagrilintide?
Side effects
| # | Reported side effect |
|---|---|
| 1 | Nausea (20% to 47% across cagrilintide doses versus 18% placebo in phase 2) |
| 2 | Gastrointestinal adverse events overall 41% to 63% versus 32% placebo in phase 2 |
| 3 | Constipation and diarrhea |
| 4 | Injection site reactions |
| 5 | In combination with semaglutide, gastrointestinal events in about half of participants (53% in REDEFINE 5) |
| 6 | Long term safety and cardiovascular outcomes not yet reported |
Interactions
| # | Interaction |
|---|---|
| 1 | No approved label, so no formal interaction studies are published |
| 2 | Delayed gastric emptying may alter absorption of oral drugs (amylin class effect, also seen with pramlintide) |
| 3 | Hypoglycemia risk when combined with insulin or sulfonylureas in people with diabetes (class precaution) |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Not approved for any use; only available inside registered clinical trials |
| 2 | Pregnancy and breastfeeding (excluded from trials) |
| 3 | Competitive athletes subject to WADA testing (prohibited under S0) |
| 4 | When combined with semaglutide, the semaglutide contraindications (medullary thyroid carcinoma, MEN2) apply |
How do people access Cagrilintide legally?
Typical cost: Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Access options
Not available
No lawful United States access path identified on the last verified date outside a registered clinical trial.
Not available
Not available as an FDA approved product and not eligible for compounding under section 503A or 503B while investigational.
Not available
Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare Cagrilintide
What's actually offered, and what that means for you
FDA has found online sellers and an ingredient distributor offering cagrilintide anyway. [15] [16] [17] [18]
Being offered does not change the legal status of cagrilintide. Cagrilintide is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [6]
What FDA found
- March 2026: FDA found an online seller offering cagrilintide with weight-loss claims, and called it an unapproved new drug despite research-only disclaimers. [17]
- December 2025: FDA's letter to a bulk ingredient distributor that supplied compounders names cagrilintide acetate. [18]
- December 2024: FDA found an online seller offering cagrilintide alone and mixed with semaglutide, and called these unapproved new drugs despite research-use-only labels. [15]
- December 2024: FDA found an online seller promoting cagrilintide with semaglutide for weight loss, and called it an unapproved new drug. [16]
Enforcement is uneven. FDA mostly acts through warning letters to online sellers and import alerts that let it detain shipments, rather than stopping every seller. State pharmacy boards oversee pharmacies day to day, and their rules differ. [19] [20] [21]
What that means for you
- Anyone who sells cagrilintide outside a registered trial is taking a regulatory risk: FDA treats it as an unapproved new drug and has sent warning letters to sellers. [19]
- No FDA oversight of the product: a product sold outside a trial is an unapproved drug, and FDA has not checked its safety, effectiveness, or quality. [19]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [22]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [23] [24]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [19]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, cagrilintide is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [7]
If you're going ahead anyway
The only safe route to cagrilintide is a registered clinical trial. No step below makes a product sold outside a trial lawful or safe.
What a research-use-only product means. A product labeled "research use only" has no prescription, no pharmacist, and no FDA review, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. [25] [26] [27] [28]
Cagrilintide is not approved in the US, and no check makes a product sold outside a clinical trial lawful. Check for:
- Enrollment in a registered clinical trial (ClinicalTrials.gov lists them). Outside a trial, any product sold as cagrilintide is an unapproved drug.
- Labels such as "research use only" or "not for human consumption", which FDA does not accept for products sold for people. [19]
- A licensed prescriber's view on whether an approved drug fits your goal.
Questions to ask
- Study team: Is this a registered clinical trial, and what is its ClinicalTrials.gov number?
- Anyone offering it: Is it labeled "research use only" or "not for human consumption"? Then it is not a pharmacy product, and FDA treats it as an unapproved drug. [25]
- Seller: Do you require a prescription, and is there a licensed pharmacist I can speak to? A seller that needs neither is a warning sign. [29]
- Anyone offering it: Does anyone call cagrilintide "FDA approved"? It is not approved in the US, so the claim is false. [6]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [22]
For weight management, approved GLP-1 drugs such as tirzepatide and semaglutide are available by prescription. See Tirzepatide, Semaglutide, GLP-1 hub.
Frequently asked questions
Is cagrilintide or CagriSema FDA approved?
No. Cagrilintide is investigational and not approved by FDA as of September 2026, alone or combined with semaglutide (CagriSema). The manufacturer submitted a new drug application (the formal request for FDA approval) for the combination in December 2025; a submission is not an approval. Neither form can be compounded (custom-made by a pharmacy), because cagrilintide is not a component of an approved product and is not on any FDA bulks list, so the only lawful access is a registered clinical trial. Products sold online as cagrilintide are unapproved drugs with no verification of identity or dose, and none has a lawful price. [5] [6] [9]
What is CagriSema?
CagriSema is the development name for cagrilintide 2.4 mg and semaglutide 2.4 mg given together once weekly in one injection. It pairs an amylin analog with the GLP-1 drug in Wegovy, two appetite pathways at once. In the 68 week REDEFINE 1 trial of 3,417 adults without diabetes, it produced 20.4% weight loss versus 3.0% on placebo. It is investigational: the manufacturer filed for FDA approval in December 2025, and no approval had been granted as of September 2026. [2] [9]
How much weight do people lose on cagrilintide?
Alone, in the 26 week phase 2 trial of 706 adults, weight loss ranged from 6.0% at 0.3 mg to 10.8% at 4.5 mg versus 3.0% on placebo, and 4.5 mg beat liraglutide 3.0 mg (9.0%). Combined with semaglutide 2.4 mg in REDEFINE 1, a 68 week phase 3 trial of 3,417 adults, the estimated mean weight loss was 20.4% versus 3.0% on placebo. In the East Asian REDEFINE 5 trial the combination beat semaglutide alone by 6.5 percentage points (18.4% versus 11.9%). [1] [2] [3]
What are the side effects of cagrilintide?
Mostly gastrointestinal. In the phase 2 monotherapy trial, 41% to 63% of cagrilintide participants had gastrointestinal adverse events versus 32% on placebo, mainly nausea (20% to 47% versus 18%), plus constipation, diarrhea, and injection site reactions. With semaglutide in REDEFINE 2, 72.5% reported gastrointestinal events versus 34.4% on placebo, most transient and mild or moderate. Long term safety and cardiovascular outcomes have not been reported. [1] [3] [8]
Does CagriSema help type 2 diabetes?
Phase 3 data say it lowers weight and blood sugar. In REDEFINE 2, 1,206 adults with type 2 diabetes and overweight or obesity lost 13.7% of body weight at 68 weeks on cagrilintide 2.4 mg plus semaglutide 2.4 mg versus 3.4% on placebo, and 73.5% reached an HbA1c of 6.5% or less versus 15.9%. An earlier 32 week phase 2 trial of 92 adults found better glucose control with the combination than with either drug alone. It is not approved for diabetes. [4] [8]
Cagrilintide vs semaglutide: what is the difference?
They work on different pathways. Semaglutide is an approved GLP-1 receptor agonist; cagrilintide is an investigational amylin analog. Alone, cagrilintide 4.5 mg produced 10.8% weight loss at 26 weeks, less than semaglutide 2.4 mg at 68 weeks (about 15%), but the two together (CagriSema) reached 20.4% in REDEFINE 1 and beat semaglutide alone by 6.5 points in REDEFINE 5. The combination is the product in development, not cagrilintide by itself. [1] [2] [3]
Is cagrilintide banned by WADA?
Yes. Cagrilintide has no approval from any government health authority, so it is prohibited at all times under section S0 (non-approved substances) of the WADA Prohibited List. This differs from approved GLP-1 agonists, which are not prohibited. [7]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
From the blog
- Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. Lancet 2021PubMed 34798060, 2021
- [2]Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med 2025 (REDEFINE 1)PubMed 40544433, 2025
- [3]Yamauchi T et al. Co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity in Japan and Taiwan (REDEFINE 5). Lancet Diabetes Endocrinol 2026PubMed 42009015, 2026
- [4]Frias JP et al. Co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes: a phase 2 trial. Lancet 2023PubMed 37364590, 2023
- [5]FDA: concerns with unapproved GLP-1 drugs used for weight lossFDA, 2025
- [6]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [7]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [8]Davies MJ et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med 2025 (REDEFINE 2)PubMed 40544432, 2025
- [9]Manufacturer press release: new drug application submitted to FDA for once weekly cagrilintide 2.4 mg plus semaglutide 2.4 mg (December 18, 2025), accessed 2026-09-222025
- [10]Manufacturer company announcement: REDEFINE 4 headline results (February 23, 2026), not peer reviewed2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 27). Cagrilintide: evidence, legality, and access. https://peptideagent.ai/peptides/cagrilintide- HTML link
<a href="https://peptideagent.ai/peptides/cagrilintide">Cagrilintide: evidence, legality, and access</a>, PeptideAgent, updated September 27, 2026.